Spojené státy - angličtina - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - atenolol 25 mg - atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mech

Spojené státy - angličtina - NLM (National Library of Medicine)

blenheim pharmacal, inc. - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - atenolol 25 mg - atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mech

Spojené státy - angličtina - NLM (National Library of Medicine)

tya pharmaceuticals - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - atenolol 25 mg - atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mech

Spojené státy - angličtina - NLM (National Library of Medicine)

rebel distributors corp - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - atenolol 100 mg - atenolol tablets, usp are indicated in the management of hypertension. it may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. atenolol tablets, usp are indicated for the long-term management of patients with angina pectoris. atenolol tablets, usp are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. treatment can be initiated as soon as the patient’s clinical condition allows (see dosage and administration, contraindications, and warnings). in general, there is no basis for treating patients like those who were excluded from the isis-1 trial (blood pressure less than 100 mm hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. as noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm hg) seemed less likely to benefit. atenolol is contraindicated in sinus bradycardia, hear

Spojené státy - angličtina - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - atenolol 25 mg - atenolol tablets, usp are indicated in the management of hypertension. it may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. atenolol tablets, usp are indicated for the long-term management of patients with angina pectoris. atenolol tablets, usp are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. treatment can be initiated as soon as the patient’s clinical condition allows (see dosage and administration, contraindications, and warnings). in general, there is no basis for treating patients like those who were excluded from the isis-1 trial (blood pressure less than 100 mm hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. as noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm hg) seemed less likely to benefit. atenolol is contraindicated in sinus bradycardia, hear

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - atenolol, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; propyl hydroxybenzoate; saccharin sodium; purified water; citric acid monohydrate; sorbitol solution (70 per cent) (non-crystallising); sodium citrate dihydrate; methyl hydroxybenzoate; flavour - all grades of hypertension including hypertension of renal origin.,frequent disabling angina without evidence of cardiac failure,cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those with acute myocardial infarction),myocardial infarction - late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)

Spojené státy - angličtina - NLM (National Library of Medicine)

redpharm drug inc. - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - atenolol 100 mg - atenolol is indicated in the management of hypertension. it may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. atenolol is indicated for the long-term management of patients with angina pectoris. atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. treatment can be initiated as soon as the patient’s clinical condition allows (see dosage and administration, contraindications, and warnings). in general, there is no basis for treating patients like those who were excluded from the isis-1 trial (blood pressure less than 100 mm hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. as noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm hg) seemed less likely to benefit. atenolol is contraindicated in sinus bradycardia, heart block greater than first de

Spojené státy - angličtina - NLM (National Library of Medicine)

aurobindo pharma limited - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti) - atenolol 25 mg - hypertension atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. atenolol tablets may be administered with other antihypertensive agents. angina pectoris due to coronary atherosclerosis atenolol tablets are indicated for the long-term management of patients with angina pectoris. acute myocardial infarction atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. treatment can be initiated as soon as the patient’s clinical condition allows. (see dosage and administration , contraindications , and warnings .) in general, there is no basis for treating patients like those who were excluded from the isis-1 trial (blood pressure less than 100 mmhg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. as noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mmhg) seemed less likely to benefit. atenolol tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure. (see warnings .) atenolol tablets are contraindicated in those patients with a history of hypersensitivity to the atenolol or any of the drug product’s components.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atenolol -

Spojené státy - angličtina - NLM (National Library of Medicine)

actavis pharma, inc. - atenolol (unii: 50vv3vw0ti) (atenolol - unii:50vv3vw0ti), chlorthalidone (unii: q0mqd1073q) (chlorthalidone - unii:q0mqd1073q) - atenolol 50 mg - atenolol and chlorthalidone is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. this fixed dose combination drug is not indicated for initial therapy of hypertension. if the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. atenolol and chlorthalidone tablets are contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (see warnings ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs.